



REBOUND HYPERBILIRUBINEMIA AFTER PHOTOTHERAPY

Thesis

Submitted For Fulfillment of MSc Degree in Pediatrics

By

Mohamed Abd El-Halim Abd El-Aal

(M.B., B.Ch)

Supervised by

Prof. Dr. Zahraa Mohamed Ezz-Eldin

**Professor of Pediatrics
Faculty of Medicine
Cairo University**

Prof. Dr. Yasmeeen Amr Mansi

**Assistant Professor of Pediatrics
Faculty of Medicine
Cairo University**

Dr. Reem Ibrahim Ismail

**Lecturer of Pediatrics
Faculty of Medicine
Cairo University**

**Faculty of Medicine
Cairo University
2012**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا
عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

البقرة .. آية رقم ٣٢

بسم الله الرحمن الرحيم

بناء على موافقة الأستاذ الدكتور / نائب رئيس الجامعة بتاريخ ٢٦ / ٧ / ٢٠١٢

اجتمعت اللجنة المشكلة من السادة الأساتذة :

الأستاذ الدكتور / زهراء محمد عز الدين أستاذ طب الأطفال - كلية الطب - جامعة القاهرة (عن المشرفين
الأستاذ الدكتور / محمد السيد هاشم أستاذ طب الأطفال - كلية الطب - جامعة القاهرة (ممتحن داخلي
الأستاذ الدكتور / محمد سامي الشيمي أستاذ طب الأطفال - كلية الطب - جامعة عين شمس (ممتحن خارجي

بقاعة الدور التاسع بمستشفى الأطفال الجامعي بالمنيرة - أبو الريش لمناقشة رسالة الماجستير في طب الأطفال المقدمة من:

الطبيب / محمد عبد الحليم عبد العال

وذلك في تمام الساعة العاشرة صباحا يوم الأربعاء الموافق ٢٦ / ٩ / ٢٠١٢

عنوان الرسالة :

ارتفاع نسبة الصفراء بعد العلاج الضوئي

الملخص :

صفراء حديثي الولادة مشكله شائعته تحدث في حوالي ٦٠٪ من الأطفال الرضع كاملي النمو و ٨٠٪ من الخدج في الأسبوع الأول من الحياه. وكان الهدف من هذه الدراسه تحديد ما إذا كان يحدث إرتفاع في نسبة الصفراء في الدم في غضون ٢٤ ساعة بعد توقف العلاج الضوئي في حديثي الولاده. وأجريت الدراسه على ١٣٣ طفل حديث الولاده من كاملي النمو والخدج تم علاجهم بالعلاج الضوئي. تم عمل إختبار لنسبة الصفراء بالدم لجميع الأطفال بعد ٢٤ (± ٦) ساعات من توقف العلاج الضوئي. وكانت نتيجة البحث حدوث إرتفاع في نسبة الصفراء بالدم في ٢١,٨٪ من حديثي الولاده بعد انتهاء العلاج الضوئي. تم تحليل الانحدار المتعدد اللوجستيه لعوامل الخطر لإرتفاع نسبة الصفراء بعد العلاج الضوئي، وتبين أهميه لإنحلال الدم (نسبة الأرجحيه ١,٢٤١) وإيجابية إختبار كومبس المباشر (نسبة الأرجحيه ٦,٣٩٢).

وترى اللجنة قبول البحث

د/ زهراء محمد

د/ محمد السيد هاشم

د/ محمد سامي الشيمي

Acknowledgement

*First of all and above all great thanks to **ALLAH**.*

*It is a great honor to me to express my deepest gratitude, extreme thankfulness and deep appreciation to **Prof. Dr. Zahraa Mohamed Ezz-Eldin**, Professor of Pediatrics, Faculty of Medicine, Cairo University for her generous help, continuous guidance and supervision, kind encouragement and valuable advice throughout the work,*

*I would like to express my deepest gratitude and thanks to **Dr. Yasmeeen Amr Mansi**, Assistant Professor of Pediatrics, Faculty of Medicine, Cairo University for her close observation, generous guidance, effective help and valuable supervision.*

*I wish to express my full thanks to **Dr. Reem Ibrahim Ismail**, Lecturer of Pediatrics, Faculty of Medicine, Cairo University for her continuous interest, generous guidance and for her kind help, that I will remain always remembering.*

ABSTRACT

Introduction: Neonatal hyperbilirubinemia is a common problem. Approximately 60% of term infants and 80% of preterm infants develop jaundice in the first week of life. Despite hyperbilirubinemia being a common morbidity among neonates, few studies have systematically studied the phenomenon of post-phototherapy rebound, data about the phenomenon of bilirubin rebound is lacking.

Objectives: The aim of this study was to determine whether a rebound in serum bilirubin level occurs within 24 hours after discontinuation of phototherapy in neonates with hyperbilirubinemia and to identify aetiological factors for hyperbilirubinemia that could be used to select infants at risk for rebound.

Study design: A prospective clinical survey was performed on 133 term and preterm neonates treated with phototherapy. Neonates were tested for T.S.B 24(\pm 6) hours after discontinuation of phototherapy, with additional testing as clinically indicated. The main outcome measure, significant bilirubin rebound, was defined as a post-phototherapy T.S.B \geq 15 mg/dl. Phototherapy was not reinstituted in all cases of rebound, but rather according to clinical indications.

Results: A total of **29** (21.8%) neonates developed significant rebound, mean (\pm SD) T.S.B was 16.45 (\pm 0.99) mg/dl. Multiple logistic regression analysis for risk factors for significant bilirubin rebound showed significant risk for aetiological risk factors including hemolysis (odds ratio 1.241, 95% CI 1.117 to 2.496) and positive direct Coombs test (odds ratio 6.392, 95% CI 1.530 to 26.706). **Sixteen** of those (55.2%) were retreated with phototherapy, mean (\pm SD) T.S.B was 16.9 (\pm 1.1) mg/dl. Multiple Logistic regression analysis for risk factors for re-admission for phototherapy showed significant risk for aetiological risk factors including hemolysis (odds ratio 1.121, 95% CI 1.048 to 2.307) and positive direct Coombs test (odds ratio 7.162, 95% CI 1.571 to 32.658). Also there was a trend for re-admission for phototherapy with weight < 2kg (odds ratio 5.976, 95% CI 0.818 to 43.685).

Conclusion: Post-phototherapy neonatal bilirubin rebound to clinically significant levels may occur, especially in cases of hemolysis, direct Coombs test positivity and low birth weight < 2kg. These risk factors should be taken into account when planning post-phototherapy follow up.

Key words: Neonatal hyperbilirubinemia – Bilirubin rebound.

List of Contents

	<i>Page</i>
List of Abbreviations	I
List of Figures	III
List of Tables	V
Introduction	1
Aim of The Work	2
Review of Literature: Chapter (1): Neonatal Hyperbilirubinemia Chapter (2): Rebound Hyperbilirubinemia	3 74
Patients and Methods	78
Results	82
Discussion	88
Summary	94
Conclusion and Recommendations	96
References	97
Arabic Summary	١

List of Abbreviations

ADCC	Antibody Dependent Cell mediated Cytotoxicity
AHT	Allogenic Hepatocyte Transplantation
ATP	Adenosine Tri-Phosphate
BIND	Bilirubin Induced Neurologic Disorders
CN	Crigler-Najjar
CO	Carbon mono-Oxide
CT	Computed Tomography
DAT	Direct Antiglobin Test
DWI	Diffusion-Weighted Imaging
ET	Exchange Transfusion
FFA	Free Fatty Acids
GA	Gestational Age
G6PD	Glucose-6-Phosphate Dehydrogenase
HDN	Hemolytic Disease of the Newborn
HO	Heme Oxygenase
HS	Hereditary Spherocytosis
IgG	Immunoglobulin G
IgM	Immunoglobulin M
IVIG	IntraVenous ImmunoGlobulin
LBW	Low Birth Weight
LEDs	Light-Emitting Diodes
MRI	Magnetic Resonance Imaging
NICU	Neonatal Intensive Care Unit
N.J	Neonatal Jaundice
NMR	Nuclear Magnetic Resonance

OD	Optical Density
PK	Pyruvate Kinase
RBCs	Red Blood Cells
Rh	Rhesus
SBR	Significant Bilirubin Rebound
TcB	Transcutaneous Bilirubin
T.S.B	Total Serum Bilirubin
UDPGT	Uridine Di-Phosphate Glucuronyl Transferase
UVC	Umbilical Vein Catheter
WHO	World Health Organization
2,3-DPG	2,3-Di-Phospho Glycerate

List of Figures

		Page
Figure (1)	Anatomy of biliary system	5
Figure (2)	Bilirubin metabolism	8
Figure (3)	Gene Therapy	18
Figure (4)	Pentose phosphate pathway	24
Figure (5)	Spherocytosis in comparison with normal RBCs	28
Figure (6)	Elliptocytosis	30
Figure (7)	Mechanism of maternal sensitization in Rh incompatibility and its prevention with anti-D	32
Figure (8)	Difference between Rh and ABO incompatibility	37
Figure (9)	Marked retrocollis and opisthotonus in a baby with kernicterus	44
Figure (10)	Bilirubin encephalopathy	47
Figure (11)	Guidelines for phototherapy in hospitalized infants of 35 or more weeks' gestation	61
Figure (12)	A neonate on conventional phototherapy	62

Figure (13)	A neonate using bili-blanket	62
Figure (14)	Exchange transfusion in a jaundiced neonate	66
Figure (15)	Guidelines for exchange transfusion in infants 35 or more weeks' gestation	69
Figure (16)	Percentage of different aetiological subgroups of hyperbilirubinemia in neonates included in the study	83
Figure (17)	Percentage of different aetiological subgroups in neonates with significant bilirubin rebound	84
Figure (18)	Percentage of different aetiological subgroups in neonates re-admitted for phototherapy	86

List of Tables

		Page
Table (1)	Differential diagnosis of neonatal hyperbilirubinemia	9
Table (2)	Possible mechanisms involved in physiologic jaundice	11
Table (3)	Congenital non-hemolytic unconjugated hyperbilirubinemia: clinical syndrome	19
Table (4)	Drugs that cause significant displacement of bilirubin from albumin	21
Table (5)	WHO classification of G6PD enzyme variants	25
Table (6)	Comparison of the two most common variants of G6PD deficiency	26
Table (7)	Clinical and laboratory features of immune hemolysis due to Rh and ABO incompatibility	38
Table (8)	Factors that increase susceptibility to neuro-toxicity associated with hyperbilirubinemia	42
Table (9)	BIND-score system	46
Table (10)	Guide to dermal staining with level of bilirubin	49
Table (11)	Laboratory evaluation of neonatal hyperbilirubinemia	52
Table (12)	Follow-up assessment of hyperbilirubinemia	55
Table (13)	Risk factors for development of severe hyperbilirubinemia in infants 35 or more weeks' gestation	56

Table (14)	Recommendations for prevention of neonatal hyperbilirubinemia	57
Table (15)	Bilirubin level and management guidelines in LBW babies based on birth weight	70
Table (16)	Number of days for maturation of reticulocytes in the marrow and blood	80
Table (17)	Mode of delivery and gender	82
Table (18)	Neonatal descriptive data	82
Table (19)	Jaundice descriptive data	83
Table (20)	Association between neonatal risk factors and significant bilirubin rebound	85
Table (21)	Logistic regression analysis for risk factors for significant bilirubin rebound	85
Table (22)	Association between neonatal risk factors and re-admission for phototherapy	87
Table (23)	Logistic regression analysis for risk factors for re-admission for phototherapy	87



INTRODUCTION & AIM OF THE WORK



INTRODUCTION

Neonatal hyperbilirubinemia is a common problem. Approximately 60% of term infants and 80% of preterm infants develop jaundice in the first week of life (*Gomella et al., 2009*).

Jaundice is a common cause of readmission to hospital after early discharge of newborn babies, but fortunately only few babies have an underlying disease (*Gale et al., 2001*).

Although most newborns with jaundice are otherwise healthy, they need to be monitored because bilirubin is potentially toxic to the central nervous system. Sufficiently elevated levels of bilirubin can lead to bilirubin encephalopathy and subsequently kernicterus with devastating permanent neurodevelopmental handicaps. Fortunately, phototherapy is an effective method for the prevention or treatment of neonatal hyperbilirubinemia (*Luchtman-Jones et al., 2006*).

Phototherapy is the primary treatment in neonates with unconjugated hyperbilirubinemia and is now arguably the most widespread therapy of any kind (excluding prophylactic treatments) used in newborns. Phototherapy often averts the need for exchange transfusion and is generally regarded as safe method, the reported side effects have been subjected to extensive and controversial debate (*Vreman et al., 2004*).

Decreasing hospital length of stay is an objective sought by physicians and administrators alike and it is recommended that infants need not be kept in the hospital after discontinuation of phototherapy. However they should be followed-up to measure rebound bilirubin levels following the discontinuation of phototherapy (*Maisels and Kring, 2002*).

Data available are inadequate to formulate recommendations for or against post-phototherapy bilirubin testing. Many reports on the subject have been flawed by comprising retrospective chart reviews, analysis of rebound by determining the mean bilirubin value rather than peak post-treatment values. Lack of preset definitions for rebound or indications for retreatment are issues for further investigations (*Bansal et al., 2010*).

AIM OF THE WORK

The aim of this study was to determine whether a rebound in serum bilirubin level occurs within 24 hours after discontinuation of phototherapy in neonates with hyperbilirubinemia and to identify aetiological factors for hyperbilirubinemia that could be used to select infants at risk for rebound.